1. Oridonin, a small molecule inhibitor of cancer stem cell with potent cytotoxicity and differentiation potential.
- Author
-
Li Y, Xie J, Du X, Chen Y, Wang C, Liu T, Yi Z, Wang Y, Zhao M, Li X, and Shi S
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Cell Proliferation drug effects, Apoptosis drug effects, Antineoplastic Agents pharmacology, Tumor Suppressor Protein p53 metabolism, MCF-7 Cells, Melanoma, Experimental pathology, Melanoma, Experimental drug therapy, Leukemia, Promyelocytic, Acute pathology, Leukemia, Promyelocytic, Acute drug therapy, Female, Diterpenes, Kaurane pharmacology, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells pathology, Cell Differentiation drug effects, Zebrafish
- Abstract
Cancer stem cells (CSCs) drive malignant tumor progression, recurrence, and metastasis with unique characteristics, including self-renewal and resistance to conventional treatments. Conventional differentiation inducers, although promising, have limited cytotoxicity and may inadvertently enhance CSC stemness. To address these challenges, ongoing efforts are dedicated to developing strategies that can effectively combine both cytotoxicity and differentiation-inducing effects. In this study, we introduce oridonin (Ori), a small molecule with dual differentiation-inducing and cytotoxicity properties capable of eliminating tumor CSCs. We isolated CSCs in B16F10 cells using the Hoechst side population method and assessed the differentiation effect of Ori. Ori's differentiation-inducing effect was further evaluated using human acute promyelocytic leukemia. The cytotoxic potential of Ori against MCF-7 and B16F10 cell lines was assessed through various methods. In vivo anti-tumor and anti-CSC efficacy of Ori was investigated using mouse melanoma and CSCs melanoma models. Safety evaluation included zebrafish embryotoxicity and mouse acute toxicity experiments. As a result, Ori effectively dismantles tumorspheres, inhibits proliferation, and reduces the expression of CSC-specific markers. It induces significant differentiation, especially in the case of NB4. Additionally, Ori upregulates TP53 expression, mitigates the hypoxic tumor microenvironment, suppresses stemness, and inhibits PD-L1 expression, prompting a robust anti-cancer immune response. Ori demonstrates pronounced cytotoxicity, inducing notable pro-apoptotic effects on B16F10 and MCF-7 cells, with specific triggering of mitochondrial apoptosis. Importantly, Ori maintains a commendable biosafety record. The dual-action prowess of Ori not only induces the differentiation of CSCs but also dispatches differentiated and residual tumor cells, effectively thwarting the relentless march of tumor progression., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF